• Nenhum resultado encontrado

Glucagon-like peptide-1

Ein Hormon stellt sich vor: "Glucagon-like Peptide 1"

Ein Hormon stellt sich vor: "Glucagon-like Peptide 1"

... „Glucagon-like Peptide 1“ (GLP-1) gehört zur Familie der Inkretine: Hormone, die vom Gastrointestinaltrakt nah- rungsabhängig produziert werden und bei erhöhten Glukose- spiegeln die ...

5

STUDY OF PALM OIL AND GLUTAMINE AS FUNCTIONAL FOODS ON PEPTIDE TYROSINE TYROSINE (PYY) AND GLUCAGON-LIKE PEPTIDE 1 (GLP-1) IN OBESE PATIENTS FOLLOWING UP ON THE AMBULATORY HEALTH SERVICES OF THE PUBLIC HOSPITAL

STUDY OF PALM OIL AND GLUTAMINE AS FUNCTIONAL FOODS ON PEPTIDE TYROSINE TYROSINE (PYY) AND GLUCAGON-LIKE PEPTIDE 1 (GLP-1) IN OBESE PATIENTS FOLLOWING UP ON THE AMBULATORY HEALTH SERVICES OF THE PUBLIC HOSPITAL

... are glucagon-like peptide 1 (GLP-1) and peptide YY (PYY), which are associated with satiety, prolongation of gastric emptying, and increased insulin secretion and sensitivity ...

13

Clinical Application of Glucagon-Like Peptide 1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus

Clinical Application of Glucagon-Like Peptide 1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus

... Glucagon-like peptide 1 (GLP-1) is secreted from enteroendocrine L-cells in response to oral nutrient intake and elicits glucose- stimulated insulin secretion while suppressing ...

13

Mathematical Modeling of Interacting Glucose-Sensing Mechanisms and Electrical Activity Underlying Glucagon-Like Peptide 1 Secretion.

Mathematical Modeling of Interacting Glucose-Sensing Mechanisms and Electrical Activity Underlying Glucagon-Like Peptide 1 Secretion.

... release glucagon-like peptide 1 (GLP-1), peptide YY and other hormones with anti-diabetic and weight-reducing ...and peptide YY ...

26

Glucagon-like peptide 1 improves insulin resistance in vitro through anti-in flammation of macrophages

Glucagon-like peptide 1 improves insulin resistance in vitro through anti-in flammation of macrophages

... Glucagon-like peptide 1 (GLP-1), a kind of gut hormone, is used in the treatment of type 2 diabetes (T2D). Emerging evidence indicates that GLP-1 has anti-inflammatory activity. ...

9

Glucagon-like peptide-1 secretory function as an independent determinant of blood pressure: analysis in the Tanno-Sobetsu study.

Glucagon-like peptide-1 secretory function as an independent determinant of blood pressure: analysis in the Tanno-Sobetsu study.

... Glucagon-like peptide 1 (GLP-1), one of the incretins, is secreted from L-cells in the small intestine after meals, contrib- uting to enhancement of post-prandial insulin secretion, ...

8

The glucagon-like peptide 1 analogue Exendin-4 attenuates the nicotine-induced locomotor stimulation, accumbal dopamine release, conditioned place preference as well as the expression of locomotor sensitization in mice.

The glucagon-like peptide 1 analogue Exendin-4 attenuates the nicotine-induced locomotor stimulation, accumbal dopamine release, conditioned place preference as well as the expression of locomotor sensitization in mice.

... gastrointestinal peptide glucagon-like peptide 1 (GLP-1) is known to regulate consummatory behavior and is released in response to nutrient ...this peptide recently ...

7

MIMéTICOS DO “GLUCAGON-LIKE PEPTIDE-1” (GLP-1) E O SEU POTENCIAL FARMACêUTICO NO CONTROLO DA DIABETES TIPO 2 E DA OBESIDADE

MIMéTICOS DO “GLUCAGON-LIKE PEPTIDE-1” (GLP-1) E O SEU POTENCIAL FARMACêUTICO NO CONTROLO DA DIABETES TIPO 2 E DA OBESIDADE

... A diabetes mellitus do tipo 2 é caracterizada pela resistência à insulina e pela disfunção das células β do pâncreas. os péptidos gastrintestinais, “gastric inhibitory polypeptide” (gip) e “glucagon-like ...

9

Albiglutide, a long lasting glucagon-like peptide-1 analog, protects the rat heart against ischemia/reperfusion injury: evidence for improving cardiac metabolic efficiency.

Albiglutide, a long lasting glucagon-like peptide-1 analog, protects the rat heart against ischemia/reperfusion injury: evidence for improving cardiac metabolic efficiency.

... human glucagon-like peptide 1 (GLP-1, fragment 7– 36) that is DPP-IV resistant (alanine to glycine conversion at amino acid 8) fused with human albumin to provide a long half-life of ...

10

Glucagon-like peptide-1 receptor ligand interactions: structural cross talk between ligands and the extracellular domain.

Glucagon-like peptide-1 receptor ligand interactions: structural cross talk between ligands and the extracellular domain.

... peptic peptide was chosen for ETD fragmentation based on high abundance for the intact triply charged ion and overlap with the turn region in the crystal structure [9] (Figure 2 and Figure ...the peptide at ...

9

Letter: Expression of Glucagon-Like Peptide-1 Receptor in Papillary Thyroid Carcinoma and Its Clinicopathologic Significance ( 2014;29:536-44, Min Jung Jung et al.)

Letter: Expression of Glucagon-Like Peptide-1 Receptor in Papillary Thyroid Carcinoma and Its Clinicopathologic Significance ( 2014;29:536-44, Min Jung Jung et al.)

... from 1 to 6 (1, 0% to 4%; 2, 5% to 19%; 3, 20% to 39%; 4, 40% to 59%; 5, 60% to 79%; and 6, 80% to 100%), and the staining intensity was also rated to produce a multiplicative ...

2

Reversal of obesity and insulin resistance by a non-peptidic glucagon-like peptide-1 receptor agonist in diet-induced obese mice.

Reversal of obesity and insulin resistance by a non-peptidic glucagon-like peptide-1 receptor agonist in diet-induced obese mice.

... During the 12-week induction period with HFD, energy consumption of C57 mice was significantly increased and their body weight gained progressively, leading to moderate hypergly- cemia, glucose intolerance and ...

15

The Effect of Glucagon-Like Peptide 1 Receptor Agonists on Weight Loss in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison Meta-Analysis.

The Effect of Glucagon-Like Peptide 1 Receptor Agonists on Weight Loss in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison Meta-Analysis.

... weight loss for GLP-1 receptor agonist therapies (exenatide or liraglutide at a clinically relevant dose), which found that they were associated with a greater weight loss than control intervention (-2.9kg; 95% CI ...

14

Expression of Glucagon-Like Peptide-1 Receptor in Papillary Thyroid Carcinoma and Its Clinicopathologic Significance

Expression of Glucagon-Like Peptide-1 Receptor in Papillary Thyroid Carcinoma and Its Clinicopathologic Significance

... castle Ltd.) and antigen retrieval was achieved by incubation with Bond Epitope Retrieval Solution 1 (Leica Biosystems Newcastle Ltd.) for 20 minutes at 98˚C. Then, endogenous per- oxidase was quenched by ...

9

GLUCAGON-LIKE PEPTIDE 1: BIOChEMISTRy, SECRETION AND MAIN PhySIOLOGICAL EFFECTS

GLUCAGON-LIKE PEPTIDE 1: BIOChEMISTRy, SECRETION AND MAIN PhySIOLOGICAL EFFECTS

... the catalytic enzyme dipeptidyl peptidase iV (Dpp-iV; Dp iV; cD 26) is a 766 amino acid, membrane-associated ecto-peptidase that is widely distributed in numerous tissues (e.g. lumenal membranes of capillary endothelial ...

10

Beneficial Effects of Evogliptin, a Novel Dipeptidyl Peptidase 4 Inhibitor, on Adiposity with Increased Ppargc1a in White Adipose Tissue in Obese Mice.

Beneficial Effects of Evogliptin, a Novel Dipeptidyl Peptidase 4 Inhibitor, on Adiposity with Increased Ppargc1a in White Adipose Tissue in Obese Mice.

... a glucagon-like peptide-1 (GLP-1) analogue, on whole body composition, energy consumption, various plasma adipokines and gene expression in white adipose tissue ...

19

Intestinal and Hepatic Niemann-Pick C1-Like 1

Intestinal and Hepatic Niemann-Pick C1-Like 1

... One of proposed mechanisms is that ezetimibe treatment or NPC1L1 deletion prevents NAFLD by reducing reactive oxygen species, activating C-Jun-N-terminal kinase, and de- ceasing ER stress [47,48]. All of these ...

9

Influência do esvaziamento gástrico sobre o controle da glicemia pós-prandial: fisiologia e implicações terapêuticas.

Influência do esvaziamento gástrico sobre o controle da glicemia pós-prandial: fisiologia e implicações terapêuticas.

... and glucagon, a hormonal and neural mechanism, regulating the rate of gastric ...factors. Glucagon-like peptide-1 secretion regulates the speed of gastric emptying, contributing to the ...

3

Eficácia e Segurança dos Agonistas dos Recetores GLP-1 no Tratamento da Diabetes Mellitus Tipo 2: Revisão Sistemática

Eficácia e Segurança dos Agonistas dos Recetores GLP-1 no Tratamento da Diabetes Mellitus Tipo 2: Revisão Sistemática

... recetores glucagon-like peptide-1 (GLP-1), ou incretinomiméticos, são fármacos que mimetizam as ações das incretinas, hormonas intes- tinais que são produzidas após a ingestão de gluco- ...

11

Einstein (São Paulo)  vol.12 número2

Einstein (São Paulo) vol.12 número2

... and glucagon, a hormonal and neural mechanism, regulating the rate of gastric ...factors. Glucagon-like peptide-1 secretion regulates the speed of gastric emptying, contributing to the ...

3

Show all 10000 documents...

temas relacionados